Literature DB >> 15238073

Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage.

H Bagavant1, U S Deshmukh, F Gaskin, S M Fu.   

Abstract

Histopathology of the kidney and clinical presentation are critical factors in the diagnosis of immune-mediated glomerulonephritis (GN). The histological manifestations of glomerular injury are shared by multiple underlying mechanisms. Work from our laboratory and from other investigators shows that antinuclear, antihistone or anti-dsDNA antibodies are neither required nor sufficient for development of lupus GN. In addition, antibody to dsDNA can be generated by mechanisms other than loss of tolerance to chromatin. Genetic analyses demonstrate that although there is some interaction between autoantibody production and renal disease, the phenotypes are regulated by distinct genetic intervals. Furthermore, renal failure is not an essential outcome of the immune-complex deposition and proliferative lupus GN. These data are also supported by published studies from systemic lupus erythematosus (SLE) patients. The immune regulation of lupus GN is distinct from other organ-specific diseases and not influenced by CD25(+) or NK1.1(+) regulatory T cells. Thus, fatal GN may depend upon a kidney-reactive T-cell response that, in turn, may be regulated by gender and intrinsic end-organ factors. The data discussed in this review call for a re-evaluation of the current paradigms for pathogenesis of SLE. An interactive model separating autoimmunity from end-organ susceptibility for the pathogenesis of SLE is proposed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238073     DOI: 10.1111/j.0300-9475.2004.01463.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  A single mid-gestation exposure to TCDD yields a postnatal autoimmune signature, differing by sex, in early geriatric C57BL/6 mice.

Authors:  A Mustafa; S D Holladay; S Witonsky; D P Sponenberg; E Karpuzoglu; R M Gogal
Journal:  Toxicology       Date:  2011-09-06       Impact factor: 4.221

2.  Spontaneous lupus-like syndrome in HLA-DQ2 transgenic mice with a mixed genetic background.

Authors:  S Rashtak; E Marietta; S Cheng; M Camilleri; M Pittelkow; C David; J Grande; J Murray
Journal:  Lupus       Date:  2010-02-08       Impact factor: 2.911

Review 3.  Mesangial pathology in glomerular disease: targets for therapeutic intervention.

Authors:  Yogesh M Scindia; Umesh S Deshmukh; Harini Bagavant
Journal:  Adv Drug Deliv Rev       Date:  2010-09-07       Impact factor: 15.470

4.  ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus.

Authors:  Jared M Odegard; Leah D DiPlacido; Lark Greenwald; Michael Kashgarian; Dwight H Kono; Chen Dong; Richard A Flavell; Joe Craft
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 5.  Hepatitis B virus (HBV) and autoimmune disease.

Authors:  Ram Maya; M Eric Gershwin; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

6.  An antinuclear antibody-negative patient with lupus nephritis.

Authors:  Hyoun Ah Kim; Jae Wook Chung; Han Jung Park; Dai Yeol Joe; Hyun Ee Yim; Hae Sim Park; Chang Hee Suh
Journal:  Korean J Intern Med       Date:  2009-03       Impact factor: 2.884

7.  Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort.

Authors:  Graciela S Alarcón; Gerald McGwin; Michelle Petri; Rosalind Ramsey-Goldman; Barri J Fessler; Luis M Vilá; Jeffrey C Edberg; John D Reveille; Robert P Kimberly
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

Review 8.  The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.

Authors:  Sonal Mehra; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.